XML 69 R2.htm IDEA: XBRL DOCUMENT v3.25.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
ASSETS    
Cash and cash equivalents $ 16,835 $ 16,209
Marketable securities 5,135 15,036
Accounts receivable 501 900
Prepaid and other current assets 2,414 2,433
Total current assets 24,885 34,578
Property and equipment, net 48 72
Acquired license - intangible, net 157 192
Other assets 70 160
Total assets 25,160 35,002
Liabilities    
Accounts payable 782 1,284
Accrued liabilities 3,531 4,329
Total current liabilities 4,313 5,613
Other long-term liabilities 72 72
Total liabilities 4,385 5,685
Commitments and Contingencies (Note 14)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,627,202 and 8,409,582 shares at June 30, 2025 and December 31, 2024, respectively; and outstanding, 8,626,464 and 8,408,844 shares at June 30, 2025 and December 31, 2024, respectively 9 8
Additional paid-in capital 579,227 578,418
Treasury stock, at cost; 738 shares at June 30, 2025 and December 31, 2024 (708) (708)
Accumulated deficit (557,449) (548,066)
Accumulated other comprehensive loss (50) (81)
Total Lisata Therapeutics, Inc. stockholders' equity 21,029 29,571
Non-controlling interests (254) (254)
Total equity 20,775 29,317
Total liabilities, non-controlling interests and stockholders' equity $ 25,160 $ 35,002